LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Strona główna・Stock List・Ascendis Pharma A-S ADR

Ascendis Pharma A-S ADR

Closed

SectorHealthcare

215.17 -1.26

Buy Sell

Overview

Share price change

24h

Current

Min

213.19

Max

216.59

Key metrics
By Trading Economics
Income	-22M -61M
Sales	56M 214M
Profit margin	-28.549
Employees	1,017
EBITDA	-56M -53M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+32.87% upside

Dividends
By Dow Jones
Next Earnings	30 kwi 2026

Market Stats
By TradingEconomics
Market Cap	1.7B 14B
Previous open	216.43
Previous close	215.17

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

157.66 / 167.29 Support & Resistance

Ascendis Pharma A-S ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

15 lut 2026, 23:21 UTC

Acquisitions, Mergers, Takeovers

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

15 lut 2026, 23:45 UTC

Market Talk

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

15 lut 2026, 23:40 UTC

Market Talk

Gold Falls on Possible Position Adjustments -- Market Talk

15 lut 2026, 23:06 UTC

Earnings

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

15 lut 2026, 23:04 UTC

Earnings

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

15 lut 2026, 23:04 UTC

Earnings

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

15 lut 2026, 23:01 UTC

Earnings

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

15 lut 2026, 23:01 UTC

Earnings

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

15 lut 2026, 22:58 UTC

Earnings

Warner Bros. Lands Ninth Straight Box Office Winner With 'Wuthering Heights' -- Barrons.com

15 lut 2026, 22:53 UTC

Acquisitions, Mergers, Takeovers

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

15 lut 2026, 22:53 UTC

Acquisitions, Mergers, Takeovers

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

15 lut 2026, 22:52 UTC

Acquisitions, Mergers, Takeovers

Qube Shareholders to Receive A$5.20/Share in Cash

15 lut 2026, 22:52 UTC

Acquisitions, Mergers, Takeovers

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

15 lut 2026, 21:35 UTC

Earnings

Warner Bros. Lands Ninth Straight Box Office Winner With 'Wuthering Heights' -- Barrons.com

15 lut 2026, 20:48 UTC

Earnings

BlueScope: Will Now Target Net Debt of Up to A$1.5 Billion; Will Surpass as Needed

15 lut 2026, 20:47 UTC

Earnings

BlueScope: Expects Full Benefits of Further A$150M Cost Savings in FY 2027

15 lut 2026, 20:46 UTC

Earnings

BlueScope: Recorded Net Annualized Cost Improvements of A$190 Million in 1H

15 lut 2026, 20:45 UTC

Earnings

BlueScope Expects a One-Third Lower 2H Result From Asia Business Vs 1H

15 lut 2026, 20:44 UTC

Earnings

BlueScope Expects 15% Higher 2H Result From North America Business Vs 1H

15 lut 2026, 20:44 UTC

Earnings

BlueScope Expects Lower 2H Result From Australia Business Vs 1H

15 lut 2026, 20:43 UTC

Earnings

BlueScope Expects 2H Underlying Ebit of A$620 Million-A$700 Million

15 lut 2026, 20:42 UTC

Earnings

BlueScope Net Debt A$2.2 Million at Dec. 31

15 lut 2026, 20:42 UTC

Earnings

BlueScope 1H Underlying Ebit A$557.5 Million, Up 81% On-Year

15 lut 2026, 20:41 UTC

Earnings

BlueScope 1H Underlying Ebitda A$915.3 Million, Up 39% On-Year

15 lut 2026, 20:40 UTC

Earnings

BlueScope 1H Underlying Profit A$382.0 Million Vs A$176.4 Million Year Prior

15 lut 2026, 20:40 UTC

Earnings

BlueScope 1H Sales Revenue From Continuing Ops A$8.22 Billion, Up 4% On-Year

15 lut 2026, 20:39 UTC

Earnings

BlueScope Intends to Spend A$310 Million on Buyback, Or Other Returns if Share Repurchases Limited

15 lut 2026, 20:38 UTC

Earnings

BlueScope Targeting A$1.30/Share Annual Ordinary Dividend

15 lut 2026, 20:37 UTC

Earnings

BlueScope Targeting Shareholder Returns of A$3.00/Share in 2026

15 lut 2026, 20:37 UTC

Earnings

BlueScope Interim Dividend 65 Australian Cents/Share

Peer Comparison

Price change

Ascendis Pharma A-S ADR Forecast

Price Target

By TipRanks

32.87% upside

12 Months Forecast

Average 287.42 USD 32.87%

High 342 USD

Low 250 USD

Based on 12 Wall Street analysts offering 12 month price targets forAscendis Pharma A-S ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Based on 12 analysts giving stock ratings to Ascendis Pharma A-S ADR - Dist in the past 3 months.

Technical Score

By Trading Central

157.66 / 167.29Support & Resistance

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.